Cooke & Bieler LP Sells 111,105 Shares of Teleflex Incorporated $TFX

Cooke & Bieler LP decreased its holdings in Teleflex Incorporated (NYSE:TFX) by 11.0% in the third quarter, Holdings Channel reports. The firm owned 900,561 shares of the medical technology company’s stock after selling 111,105 shares during the period. Teleflex comprises about 1.7% of Cooke & Bieler LP’s portfolio, making the stock its 18th largest position. Cooke & Bieler LP’s holdings in Teleflex were worth $112,606,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Teleflex during the 2nd quarter worth $688,537,000. Jupiter Topco LLC acquired a new position in Teleflex during the 2nd quarter valued at about $550,456,000. Irenic Capital Management LP acquired a new position in Teleflex during the 1st quarter valued at about $104,061,000. Pzena Investment Management LLC purchased a new stake in Teleflex in the second quarter valued at about $76,462,000. Finally, Bank of America Corp DE purchased a new stake in Teleflex in the second quarter valued at about $61,156,000. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Price Performance

Shares of NYSE:TFX opened at $130.47 on Thursday. Teleflex Incorporated has a twelve month low of $100.18 and a twelve month high of $145.00. The company’s 50 day moving average is $130.95 and its 200 day moving average is $130.62. The company has a current ratio of 2.60, a quick ratio of 2.12 and a debt-to-equity ratio of 0.94. The company has a market cap of $5.53 billion, a PE ratio of -5.60, a price-to-earnings-growth ratio of 0.88 and a beta of 0.83.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.48. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The company had revenue of $570.33 million during the quarter, compared to analyst estimates of $559.59 million. During the same period last year, the firm posted $3.73 EPS. Teleflex’s revenue for the quarter was up 28.9% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. On average, sell-side analysts forecast that Teleflex Incorporated will post 7.22 EPS for the current year.

Teleflex Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Friday, August 14th were paid a $0.34 dividend. The ex-dividend date was Friday, August 14th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.0%. Teleflex’s dividend payout ratio is presently -5.84%.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Mizuho raised their price target on Teleflex from $140.00 to $145.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research note on Monday, September 21st. Wall Street Zen upgraded shares of Teleflex from a “sell” rating to a “hold” rating in a report on Sunday, August 9th. BMO Capital Markets began coverage on shares of Teleflex in a report on Wednesday, July 8th. They set an “outperform” rating and a $159.00 price objective on the stock. Finally, Truist Financial decreased their price objective on shares of Teleflex from $150.00 to $142.00 and set a “hold” rating for the company in a research report on Wednesday, October 14th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $154.40.

About Teleflex

Teleflex Incorporated is a global medical technology company that develops, manufactures and markets specialty medical devices. Its products are designed to support healthcare professionals in critical care and procedural settings, including vascular access, interventional cardiology and radiology, anesthesia, respiratory care, emergency medicine, surgical applications and urology.

The company’s portfolio includes catheters, access and closure devices, airway-management products, surgical instruments, pain-management devices and other technologies used in hospitals and outpatient facilities.